EU-CAYAS-NET consortium representatives discuss a new guideline to support the transition to long-term care for young cancer survivors.
The topical JAK inhibitor ruxolitinib has been recommended by the NICE for eligible patients with non-segmental vitiligo.
SABRE project leads discuss landmark changes in total hip BMD as a surrogate for fracture risk reduction in postmenopausal osteoporosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results